Nature Medicine, Published online: 09 January 2025; doi:10.1038/s41591-024-03431-7
An individual-based mathematical model evaluating the public health benefits of RSVpreF vaccination showed that vaccinating older adults and pregnant women can substantially reduce respiratory syncytial virus (RSV)-related hospitalizations and deaths, averting substantial inpatient costs, with the impact varying across countries and influenced by both uptake rates and the local epidemiological characteristics of RSV seasons.
